$VTGN
Vistagen Therapeutics, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$0.293
▼-20.41%-$0.075
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateVistagen Therapeutics, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is VTGN down today? It is at $0.293 (-20.41%), and our scanner flagged it 92 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment VTGN spikes, and full due diligence on VTGN — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $VTGN 92 times in the last 30 days. Create a free account to track $VTGN, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
VTGN is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 22 unusual-volume and momentum alerts on VTGN today, peaking at 41.0x its normal volume. Fresh from the SEC: Vistagen Therapeutics, Inc.: Vistagen Reports Positive Findings Supporting Fasedienol’s Potential. A material company disclosure like this is often the real catalyst behind a move of this size.
Likely catalystClinical / FDA update, from the latest SEC filing. Read it →Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
From the trading subreddits (WallStreetBets, r/stocks and more). Retail chatter, not a signal. Do your own research.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Singh Shawn Officer | Acquired (grant/award) | +37K 0.08% of company | added 100% | 55K | $7K at $0.190 | Jun 30, 26 |
Tressler Nick B. Officer | Acquired (grant/award) | +12K 0.03% of company | n/a | 12K | $2K at $0.190 | Jun 30, 26 |
Adler Reid G. Officer | Acquired (grant/award) | +37K 0.08% of company | added 100% | 61K | $7K at $0.190 | Jun 30, 26 |
Prince Joshua S. Officer | Acquired (grant/award) | +4K | added 40% | 15K | $2K at $0.560 | Dec 31, 25 |
Singh Shawn Officer | Acquired (grant/award) | +8K 0.02% of company | added 72% | 18K | $13K at $1.70 | Jun 30, 25 |
Anderson Cynthia Lynn Officer | Acquired (grant/award) | +7K 0.01% of company | added 100% | 13K | $11K at $1.70 | Jun 30, 25 |
Adler Reid G. Officer | Acquired (grant/award) | +8K 0.02% of company | added 46% | 24K | $13K at $1.70 | Jun 30, 25 |
Prince Joshua S. Officer | Acquired (grant/award) | +5K 0.01% of company | added 82% | 11K | $8K at $1.70 | Jun 30, 25 |
Anderson Cynthia Lynn Officer | Acquired (grant/award) | +3K | added 72% | 6K | $7K at $2.51 | Dec 31, 24 |
Prince Joshua S. Officer | Acquired (grant/award) | +3K | added 100% | 6K | $8K at $2.51 | Dec 31, 24 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
VTGN is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 22 unusual-volume and momentum alerts on VTGN today, peaking at 41.0x its normal volume. Fresh from the SEC: Vistagen Therapeutics, Inc.: Vistagen Reports Positive Findings Supporting Fasedienol’s Potential. A material company disclosure like this is often the real catalyst behind a move of this size.
VTGN last traded at $0.293, down 20.41% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Vistagen Therapeutics, Inc. Common Stock (VTGN) is next expected to report earnings on Thursday, November 12, 2026, about 49 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The VTGN Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged VTGN 92 times in the last 30 days.
VTGN (Vistagen Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $11M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge VTGN for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$VTGN discussion
Sign in to ask a question or join the discussion.